Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic DriversJuly 23, 2025
Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India PatentJune 25, 2025
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across IndiaJune 18, 2025